Welcome to the UPF Digital Repository

Impact of DNA damage response-targeted therapies on the immune response to tumours

Show simple item record

dc.contributor.author Lutfi, Nura
dc.contributor.author Galindo-Campos, Miguel A.
dc.contributor.author Yélamos López, José
dc.date.accessioned 2022-07-21T06:28:12Z
dc.date.available 2022-07-21T06:28:12Z
dc.date.issued 2021
dc.identifier.citation Lutfi N, Galindo-Campos MA, Yélamos J. Impact of DNA damage response-targeted therapies on the immune response to tumours. Cancers (Basel). 2021 Nov 29; 13(23): 6008. DOI: 10.3390/cancers13236008
dc.identifier.issn 2072-6694
dc.identifier.uri http://hdl.handle.net/10230/53772
dc.description.abstract The DNA damage response (DDR) maintains the stability of a genome faced with genotoxic insults (exogenous or endogenous), and aberrations of the DDR are a hallmark of cancer cells. These cancer-specific DDR defects present new therapeutic opportunities, and different compounds that inhibit key components of DDR have been approved for clinical use or are in various stages of clinical trials. Although the therapeutic rationale of these DDR-targeted agents initially focused on their action against tumour cells themselves, these agents might also impact the crosstalk between tumour cells and the immune system, which can facilitate or impede tumour progression. In this review, we summarise recent data on how DDR-targeted agents can affect the interactions between tumour cells and the components of the immune system, both by acting directly on the immune cells themselves and by altering the expression of different molecules and pathways in tumour cells that are critical for their relationship with the immune system. Obtaining an in-depth understanding of the mechanisms behind how DDR-targeted therapies affect the immune system, and their crosstalk with tumour cells, may provide invaluable clues for the rational development of new therapeutic strategies in cancer.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher MDPI
dc.rights Copyright: © 2021, Lutfi N, Galindo-Campos MA, Yélamos J.. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http:// creativecommons.org/licenses/by/ 4.0/)
dc.rights.uri http:// creativecommons.org/licenses/by/ 4.0
dc.title Impact of DNA damage response-targeted therapies on the immune response to tumours
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.3390/cancers13236008
dc.subject.keyword DNA damage response-targeted agents
dc.subject.keyword Immune response
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking